In low-income countries, infectious diseases still account for a large proportion of deaths,
highlighting health inequities largely caused by economic differences. Vaccination can cut …

… Ipilimumab induces T-cell proliferation and de-novo anti-tumour T-cell responses, including
in memory T cells, whereas nivolumab restores the function of existing anti-tumour T cells. …

Background Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the
epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing …

Background Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and
C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive …

Background Osimertinib is standard-of-care therapy for previously untreated epidermal
growth factor receptor (EGFR) mutation–positive advanced non–small-cell lung cancer (NSCLC). …

… The investment opportunities of the firm materialize at t = 1 . For … I dollars made at t = 1 results
in a return of I dollars at t = 2 (a … This project requires an investment I to be made at t = 1 and …

Objective: To identify risk factors associated with cancer-specific survival and develop a
predictive model for patients undergoing primary hepatic resection for metastatic colorectal …

Purpose: Panitumumab, a fully human antibody against the epidermal growth factor
receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). …

Aims The original Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD)
Axis I diagnostic algorithms have been demonstrated to be reliable. However, the …

We combine theory and experiment to demonstrate that a carefully designed gradient meta-surface
supports high-efficiency anomalous reflections for near-infrared light following the …